Therefore, the current study assessed the effects of sFLT-1 treatment in the presence or absence of CALCA on mitochondrial function in OASMCs isolated from women with normal pregnancy and identified if mice that over-express sFLT-1 during pregnancy in the presence of continuous infusion of CALCA are protected from development of PE-like symptoms such as elevated blood pressure (BP), ATII hypersensitivity, fetal growth restriction, and an elevated albumin–creatinine ratio in mice. This evidence concerns the gene CALCA and fetal growth restriction.